🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/05/2023 | 347,50 | 347,93 | 342,06 | 345,15 | -1,00% | 1,69% | 827.900 |
| 15/05/2023 | 348,00 | 351,74 | 347,03 | 348,65 | +0,36% | 1,35% | 691.000 |
| 12/05/2023 | 350,42 | 351,98 | 345,80 | 347,41 | -0,85% | 1,76% | 509.200 |
| 11/05/2023 | 350,57 | 351,60 | 347,35 | 350,40 | +0,10% | 1,21% | 787.600 |
| 10/05/2023 | 348,00 | 352,47 | 346,17 | 350,04 | +1,51% | 1,81% | 1.199.200 |
| 09/05/2023 | 343,29 | 346,49 | 342,66 | 344,83 | +0,22% | 1,12% | 871.000 |
| 08/05/2023 | 347,62 | 347,93 | 340,79 | 344,09 | -1,15% | 2,05% | 707.900 |
| 05/05/2023 | 346,89 | 350,54 | 345,01 | 348,09 | +0,43% | 1,59% | 1.119.400 |
| 04/05/2023 | 347,97 | 349,13 | 345,01 | 346,59 | +0,07% | 1,18% | 927.800 |
| 03/05/2023 | 349,28 | 352,23 | 342,34 | 346,36 | +0,10% | 2,83% | 1.226.400 |
| 02/05/2023 | 345,00 | 354,46 | 344,39 | 346,03 | +0,30% | 2,92% | 2.002.000 |
| 01/05/2023 | 340,22 | 345,69 | 339,78 | 345,00 | +1,25% | 1,74% | 1.489.000 |
| 28/04/2023 | 338,50 | 346,29 | 338,35 | 340,73 | +0,40% | 2,35% | 1.455.400 |
| 27/04/2023 | 324,50 | 340,22 | 324,50 | 339,37 | +4,97% | 4,84% | 2.518.600 |
| 26/04/2023 | 326,50 | 327,23 | 316,43 | 323,30 | -2,60% | 3,31% | 1.572.700 |
| 25/04/2023 | 334,50 | 336,25 | 331,18 | 331,93 | -0,27% | 1,52% | 842.200 |
| 24/04/2023 | 331,05 | 333,86 | 329,84 | 332,84 | +0,53% | 1,21% | 597.000 |
| 21/04/2023 | 330,89 | 335,28 | 330,25 | 331,09 | +0,59% | 1,52% | 925.000 |
| 20/04/2023 | 326,79 | 330,47 | 326,68 | 329,15 | +0,21% | 1,16% | 812.200 |
| 19/04/2023 | 326,79 | 330,15 | 325,19 | 328,45 | +1,01% | 1,52% | 796.400 |
| 18/04/2023 | 328,00 | 328,00 | 323,38 | 325,15 | -0,79% | 1,41% | 957.500 |
| 17/04/2023 | 335,00 | 335,00 | 327,09 | 327,74 | -1,73% | 2,36% | 1.044.700 |
| 14/04/2023 | 332,96 | 334,18 | 331,37 | 333,52 | +0,05% | 0,84% | 931.000 |
| 13/04/2023 | 326,97 | 334,09 | 326,01 | 333,35 | +2,14% | 2,47% | 1.259.300 |
| 12/04/2023 | 324,36 | 327,98 | 323,98 | 326,37 | +0,47% | 1,23% | 988.800 |
| 11/04/2023 | 324,17 | 324,97 | 321,40 | 324,83 | +0,49% | 1,10% | 649.800 |
| 10/04/2023 | 320,48 | 323,45 | 318,02 | 323,24 | +0,49% | 1,69% | 665.700 |
| 06/04/2023 | 321,41 | 324,65 | 321,13 | 321,66 | -0,09% | 1,10% | 912.000 |
| 05/04/2023 | 316,40 | 322,10 | 314,33 | 321,94 | +2,39% | 2,46% | 1.126.100 |
| 04/04/2023 | 315,56 | 318,85 | 313,47 | 314,42 | -0,60% | 1,70% | 952.200 |